Toronto, ON – September 3, 2025 - PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC:MDXXF), a biotechnology company focused on the research, development, and manufacturing of novel MDXX class molecules (including its LaNeo™ MDMA), is pleased to announce that it has incorporated PharmAla Biotech Australia Pty Ltd. (“PharmAla Australia”), a wholly-owned Australian subsidiary, for the purposes of conducting research and development activities in Australia.
“As many know, Australia continues to be a thriving market for biotech development. We believe that our familiarity with the market – our relationships and our experience - will drive significant synergies,” said Nick Kadysh, Founding CEO, PharmAla Biotech.
PharmAla Australia will receive a full and perpetual license to the company’s ALA-002 asset and all associated patents, and will be positioned to execute both manufacturing development and clinical research in Australia.
“While we see Australia as having a very strong set of experts in clinical research and drug discovery, we are confident it also has an exceptional regulatory environment for launching clinical trials,” said Will Avery, CFO, PharmAla Biotech. “PharmAla Australia will benefit from that, as well as a growing environment of biotech financiers and government incentives.”
Appointment of Dr. Evan Lewis to PharmAla’s Scientific Advisory Board
PharmAla has appointed Dr. Evan Lewis (MD, FRCPC, CSCN EEG Diplomate, CMLE, C-CAT (P)) to its Scientific Advisory Board, effective September 1, 2025.
Dr. Evan Cole Lewis is an adult and pediatric neurologist with specialized training in epilepsy and pediatric neurology. He holds a clinical appointment as Adjunct Assistant Professor in the Department of Pediatrics at the Hospital for Sick Children and the University of Toronto. He founded and led the Neurology Centre of Toronto (2016–2024) and served as Vice President of Psychedelic Neurology at Numinus (2021–2024), where he advanced clinical care and research in medical cannabis and developed and directed a Ketamine-Assisted Therapy program for neurological conditions.
His clinical focus includes epilepsy, brain injury, concussion and persistent post-concussion symptoms, functional neurological disorders—especially functional seizures—and the use of cannabis and psychedelics in neurological treatment.